Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999654 | 0.90 | GLA (0.61) | GLAHSD17B10ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL9795225 | 0.86 | HSD17B10 (0.56) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL16353821 | 0.85 | SMN1; SMN2 (0.59) | ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL1726735 | 0.84 | TSHR (0.57) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL8190979 | 0.84 | HSD17B10 (0.55) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL18381272 | 0.84 | CYP1A2 (0.62) | ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL2811459 | 0.83 | TSHR (0.56) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL24686241 | 0.82 | HSD17B10 (0.59) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL26393724 | 0.82 | FAAH (0.55) | HSD17B10ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL9633498 | 0.82 | FAAH (0.55) | HSD17B10ALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | disclosed |
| CN-100543032-C | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2009-09-23 | — | — | CN | disclosed |
| CN-1961878-A | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA SA (FR) | 2007-05-16 | — | — | CN | disclosed |
| US-7166594-B2 | Antibacterial activity | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2003-08-07 | — | — | US | disclosed |
| US-6569854-B1 | Virginamycins | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
| CN-1358194-A | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2002-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | GLA 950/4885HSD17B10 1991/4885ALDH1A1 1193/4885 |
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | MRPL21, ABHD5, APEH | GLA 151/4885HSD17B10 548/4885ALDH1A1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.